Inve India ▾

Gufic Biosciences share price & results

Gufic Biosciences Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

One of India's largest lyophilized-injection makers; also botulinum toxin, fertility drugs, APIs and CMO

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue261 ₹ crore+15.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin18.0 %+4.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit22.0 ₹ crore+83.3% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity11.53 %−2.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin1.46 %−4.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)16.65 %+13.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 11 judged targets kept · 16 open · verdicts reflect calls analysed to Q1 FY27.

Gufic Biosciences Limited management guidance track record on Inve: 27 targets tracked across analysed earnings calls (4 achieved, 7 missed, 16 open).

TargetOriginal wordingSaidLatest callVerdict
Indore Revenue (FY26)Minimum INR 150 crores additional revenue
Call transcript, Q3 FY25 · 17 Feb 2025		Q3 FY25Q1 FY27:Promise for FY26 has been achieved per prior quarter analysis. No further updates.
Call transcript, Q1 FY27 · 17 Aug 2026		Achieved*
Indore US FDA Action TimelineCalendar year 2026
Call transcript, Q2 FY25 · 18 Nov 2024		Q2 FY25Q1 FY27:No specific mention of the US FDA timeline or inspection trigger.
Call transcript, Q1 FY27 · 17 Aug 2026		Ghosted
Indore EU Approval TimelineBy end of 2025
Call transcript, Q2 FY25 · 18 Nov 2024		Q2 FY25Q1 FY27:The Indore certificate... we are just waiting for the feedback from the authority... hopefully, in the next maybe a month or 2, we should be hearing something from them.
Call transcript, Q1 FY27 · 17 Aug 2026		Delayed

Source: Inve Guidance Tracker for Gufic Biosciences Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of Gufic Biosciences Limited's 27 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 24 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹420.45 +3.22% · +₹13.1

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +23.0% 1Y

₹300₹350₹400₹450Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 16 Feb 2026Q4 FY26 — 1 Jun 2026Q1 FY27 — 17 Aug 2026

1Y: ₹341.7 on 24 Oct 2025 → ₹420.45. High ₹448 (7 Sept 2026), low ₹273.5 (4 Mar 2026).

Previous close
₹407.35
Market cap
₹4.1k Cr
52-week range
₹273.5 – ₹448
One year
+25.32%
Price to earnings (TTM to Jun 2026)
55.96×
Return on equity (TTM to Jun 2026)
11.53%

Overview

Symbol
NSE:GUFICBIO
Exchange
NSE
Currency
INR

What Gufic Biosciences Limited does

Based on the company's own presentations, annual report and earnings calls.

Gufic Biosciences is a research-based pharmaceutical company and one of India's largest manufacturers of lyophilized (freeze-dried) injectable drugs, alongside natural/herbal and nutraceutical formulations. It runs four business lines: branded domestic formulations sold through a large field force across critical-care, women's health/fertility, botulinum toxin (aesthetics and neurology) and pain/GI/nutraceutical categories; contract manufacturing (CMO) of injectables for other pharma companies; bulk drug/API manufacturing (anesthetics, antifungals, antibiotics); and an international business that registers, licenses and exports products worldwide. Manufacturing is spread across dedicated facilities in Navsari (Gujarat), Belgaum (Karnataka) and a newer complex-injectables plant in Indore (Madhya Pradesh) built for regulated markets such as the US and EU.

Segments

  • Domestic Business
  • CMO Business
  • Bulk Drug (API) Business
  • International Business
Manufacturing facilities
4 dedicated plants — Navsari Unit I & II (Gujarat), Belgaum (Karnataka) and Indore (Madhya Pradesh), plus a dedicated Penem/Carbapenem block and a separate API facility
Indore facility installed capacity
60mn lyophilized vials/yr + 120mn liquid ampoules/yr + 72mn liquid vials/yr, built to regulated-market (US/EU) standards
Navsari installed capacity (Units I & II)
48mn lyophilized vials/yr combined + 12mn ampoules/yr + 32.8mn pre-filled syringes/yr, incl. liposomal Amphotericin B and depot injections
Field force
~1,000+ representatives across 8 domestic strategic business units
Domestic reach
100+ SKUs, 30,000+ prescribers, 1,10,000+ retail outlets, 1,20,000+ doctors reached, 80% of tertiary-care hospital coverage
CMO partner base
70+ partner companies, 150+ products manufactured across multiple therapy areas
Founded 1984Headquarters Mumbai, Maharashtra, IndiaEmployees 1,988 (2025-03-31)

How the price took the results

close before → close after

Q1 FY27
−0.9%
17 Aug
Q4 FY26
+3.8%
1 Jun
Q3 FY26
−5.3%
16 Feb
Q2 FY26
−1.5%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Gufic Biosciences Limited

Free account: one company. Everything above stays public.

Write why you follow Gufic Biosciences Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Gufic Biosciences Limited

Guides on how to read this kind of business and the numbers that matter.